2025 Global MedTech 100 Unveiled: Three Strategic Signals Reshaping the Industry

On September 18, authoritative industry media Medical Design & Outsourcing released a significant ranking — the 2025 Global Top 100 Medical Device Companies list. While Medtronic and Johnson & Johnson still hold the top two positions firmly, the top ten spots have seen dramatic changes; meanwhile, the two Chinese companies that made the list are quietly reshaping the global competitive landscape.

1. Global Top Ten Shuffle: The "Offensive and Defensive Battle" of U.S. Giants

This year's top ten list is a "major shake-up," with American companies still holding absolute dominance, but the changes in ranking conceal intriguing implications:

• Securely holding the top two positions
  Medtronic (1st) and Johnson & Johnson Medical Technologies (2nd) have remained at the top for two consecutive years, but the "iron throne" is showing signs of instability — Medtronic is planning to spin off its $2.8 billion diabetes business into an independent company named “MiniMed,” which will likely cause it to lose the leading position after the divestiture.
  

• Biggest Dark Horse Comeback
  Medline Industries surpasses Siemens Healthineers, jumping from 4th place last year to 3rd;

• New Faces Break into the Top Ten
  Boston Scientific rose from 11th to 9th, BD Medical (Medical and Interventional Business) jumped from 12th to 10th, while Baxter, which was 10th last year, fell to 14th.

Compared with the 2024 list, global giants are seizing opportunities through spin-offs and reorganizations — GE Healthcare rises to 6th place, Philips drops to 7th, and industry concentration further increases.

II. China's Two Powerhouses Breakthrough Against the Trend: The "Advancement Code" of Mindray and MicroPort

Against the backdrop of intensifying global competition, two Chinese companies achieved a dual ranking upgrade, using data to demonstrate the resilience of "Made in China."

(Chart 1: Comparison of Rankings and Revenue for Chinese Companies 2024-2025)

Note: The ranking data source is Medical Design & Outsourcing; revenue data comes from annual corporate reports and industry forecasts, with the estimated 2025 revenue based on the actual values of the 2024 fiscal year.

It is clear that Mindray Medical, with its revenue exceeding 5 billion US dollars, has steadily climbed 2 positions; while MicroPort Medical, with a year-on-year revenue growth of 25.6%, achieved a leap of 3 positions. There is a significant positive correlation between revenue growth and ranking improvement.

(Chart 2: Revenue Comparison Between China's Top Two and the World's Top Three Enterprises in 2024)

Note: Data sources are from the company's 2024 fiscal year annual report and the Medical Design & Outsourcing list.

The comparison chart shows that China's top two companies still lag behind global giants in terms of revenue scale (Mindray's revenue is approximately 13.2% of Medtronic's), but their investment intensity in R&D (Mindray's R&D accounts for 13%, while Medtronic's R&D accounts for 9.3%) has become competitive, laying the foundation for a breakthrough in subsequent rankings.

▶Mindray Medical (25th, ↑2): Internationalization withstands pressure

As the leading medical device company in China, Mindray's performance is a "model of逆势 growth":

• Key data highlights: Fiscal year 2024 revenue reached $5.01 billion, with R&D investment exceeding $557 million, marking a significant increase from last year's revenue of $4.289 billion.
• Effectiveness of Overseas Expansion: Despite experiencing the first dual decline in mid-term performance since its listing in the first half of 2025, overseas business now accounts for 50%, with international revenue growing by 5.39% year-on-year in the first half. Among its production bases spread across 14 countries, operations have commenced in 11 countries. This "China R&D + Overseas Manufacturing" model has effectively withstood trade fluctuations.
• Capital Moves Intensify: Preparing for Secondary Listing in Hong Kong, Aiming to Raise Over US$1 Billion; Future Global Resource Integration Capabilities Set to Upgrade.

▶ MicroPort Medical (70th, ↑3): Narrowing Losses Bring Hope

Though still not profitable, MicroPort has released positive signals:

• Revenue of $1.03 billion in fiscal year 2024, R&D investment of $217 million, and the mid-year report for 2025 shows a year-over-year loss narrowing by more than 50%, even achieving a profit of $1.221 million under non-International Financial Reporting Standards;
• Overseas Markets Become Core Engine: Overseas Revenue Surged 85% Year-on-Year in 2024, International Strategy Gradually Paying Off.
  
  

3. Beyond the Rankings: The "Long Slope and Steep Slope" of Chinese Medical Devices

In this list, only two Chinese companies, Mindray and MicroPort, made the cut, while highly anticipated companies like United Imaging were absent, reflecting the current state of the industry:

• Significant progress but gaps remain
  Mindray, while ranking first in China, still has a gap compared to Medtronic (with revenue of $32.364 billion) and Johnson & Johnson (with revenue of $30.4 billion);

• R&D investment is the key
  Mindray's R&D investment of $5.57 billion, though leading in China, is only about one-fifth of Medtronic's (which invested over $30 billion in R&D in 2024).

• Internationalization is a must-answer question
  As can be seen from the growth paths of Mindray and MicroPort, overseas markets have become the core battleground for Chinese device companies to break through scale bottlenecks.
  
  
  The "Next Stop" for Chinese Devices on the Global Stage

The 2025 Top 100 List is both a "strategic barometer" for global giants and a "growth report card" for Chinese device companies. Medtronic's spin-off, Johnson & Johnson's buildup, Mindray's overseas expansion, and MicroPort's loss reduction all point to the same trend —Technological innovation and global layout will be the core moat of future competition.。

For Chinese companies, the advances of Mindray and MicroPort are just the beginning. As R&D investment continues to increase and overseas channels are further developed, more "Chinese faces" may break into the top ranks of the global top 100 in the future. Who do you think will be the next Chinese medical device company to enter the top 100? Feel free to share your thoughts in the comment section!